CLINICAL_TRIALS
trial_result
· 2025-12-30
Clinical Trial Update: Post Marketing Study on Pluvicto in Korea
Summary
A post-marketing study of Pluvicto (Lutetium-177-PSMA-617) in Korea for metastatic castration-resistant prostate cancer is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration-resistant Prostate Cancer | Status: RECRUITING